Plasma cell leukemia (PCL) is a rare disease that may ... lenalidomide and transplant-based regimens will probably improve treatment outcome. There is insufficient information to support ...

The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended six novel medicines for approval at its ...

Myers Squibb. North America was the largest region in the abecma market in 2024. The regions covered in abecma report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, ...

Her treatment consisted of rhubarb pills and ... levels (≥2 times the upper level of normal), and evidence of plasma cell leukemia (defined as ≥5% circulating clonal plasma cells on peripheral ...

No dose-limiting toxicities (DLTs), ≥Grade 3 cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), or graft-versus-host disease (GVHD) were reported. The ...

The blood cancer market is experiencing robust growth, driven by rising incidence rates and advancements in targeted therapies and immuno-oncology. I ...

Miquela's diagnosis is scripted, but the crisis is real.

CT0596 is currently being evaluated in an early exploratory clinical study for relapsed/refractory multiple myeloma (R/R MM) or relapsed/refractory plasma cell leukemia (R/R PCL ... with no patients ...

Howard and Cynthia Steinberg aimed for meaningful impact when they imagined the Harold and John Steinberg Memorial Nursing ...